Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04874415
Other study ID # STUDY21040122
Secondary ID K23DK125719-01
Status Recruiting
Phase N/A
First received
Last updated
Start date November 16, 2021
Est. completion date April 1, 2025

Study information

Verified date April 2024
Source University of Pittsburgh
Contact Mary E Vajravelu, MD
Phone 412-692-6533
Email MaryEllen.Vajravelu@pitt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is an urgent need to engineer targeted physical activity interventions that are effective and scalable for obese adolescents and young adults (AYA) with type 2 diabetes (T2D), who often have very low levels of physical activity. The BEAM Trial is a proposed mobile health (mHealth) intervention that uses behavioral economic-informed financial incentives and text messaging to promote physical activity in AYA with T2D and prediabetes.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date April 1, 2025
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 13 Years to 22 Years
Eligibility Inclusion Criteria: - 1) Males or females age 13 to 22 years. - 2) Overweight or obese (BMI =85th percentile for age/sex, or =25 kg/m2 for participants =18 years) - 3) Diagnosis with prediabetes or type 2 diabetes - 4) Consent (subjects 18 and older), Parental/guardian permission (subjects 13-17), assent (subjects 13-17) - 5) Willingness to wear Fitbit during waking hours daily for duration of run-in and intervention. - 6) Possession of a smartphone. Exclusion Criteria: - 1) Potential subject unable to speak or read in English - 2) Severe cognitive impairment - 3) Permanent or temporary physical disability that impairs ambulation or precludes engagement in MVPA - 4) Current pregnancy - 5) Previously-diagnosed or current restrictive or purging eating disorder - 6) Moderate to vigorous physical activity (MVPA) >30 minutes per day or Fitbit wear < 4 days during second week of 2-week run-in period

Study Design


Intervention

Behavioral:
1RLD
1RLD=One text per day, ramped goal, loss incentive, daily goal time period
1RLW
1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
1RGD
1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
1RGW
One text per day, ramped goal, gain incentive, weekly goal time period.
2RLD
Two texts per day, ramped goal, loss incentive, daily goal time period.
2RLW
Two texts per day, ramped goal, loss incentive, weekly goal time period.
2RGD
Two texts per day, ramped goal, gain incentive, daily goal time period.
2RGW
Two texts per day, ramped goal, gain incentive, weekly goal time period.
1FLD
One text per day, fixed goal, loss incentive, daily weekly goal time period.
1FLW
One text per day, fixed goal, loss incentive, weekly goal time period.
1FGD
One text per day, fixed goal, gain incentive, daily goal time period.
1FGW
One text per day, fixed goal, gain incentive, weekly goal time period.
2FLD
Two texts per day, fixed goal, loss incentive, daily goal time period.
2FLW
Two texts per day, fixed goal, loss incentive, weekly goal time period.
2FGD
Two texts per day, fixed goal, gain incentive, daily goal time period.
2FGW
Two texts per day, fixed goal, gain incentive, weekly goal time period.

Locations

Country Name City State
United States UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pittsburgh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Moderate to Vigorous Physical Activity (MVPA) Effects of time spent in MVPA will be measured by assessing the weekly mean minutes in MVPA per day 12 weeks
Secondary Daily Step Count Daily step count will be measured by assessing the daily mean steps 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A